Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAM | P19021 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CTH | P32929 | 1/20 | 0.33 |
| ▸ | CBS | P35520 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2600792 | 0.88 | PAM (0.46) | PAMTSHRCTHCBSTHPO | |
| SCHEMBL6360573 | 0.85 | PAM (0.45) | PAMTSHRCTHCBSTHPO | |
| SCHEMBL19864349 | 0.84 | PAM (0.45) | PAMTSHRCTHCBSTHPO | |
| SCHEMBL17463468 | 0.81 | PAM (0.63) | PAMTSHRLMNASLC15A2TDP1 | |
| SCHEMBL12286302 | 0.80 | PAM (0.57) | PAMTSHRCES2LMNA | |
| SCHEMBL17463465 | 0.80 | PAM (0.68) | PAMTSHRLMNASLC15A2TDP1 | |
| SCHEMBL2600799 | 0.78 | PAM (0.54) | PAMTSHRCES2GAA | |
| SCHEMBL2612024 | 0.78 | — | — | |
| SCHEMBL12286258 | 0.77 | PAM (0.37) | PAM | |
| SCHEMBL14022135 | 0.76 | MGAM (0.52) | PAMTSHRCTHCBSTHPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026285-B2 | Control release of biologically active compounds from multi-armed oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2011-09-27 | — | — | US | disclosed |
| US-20090076174-A1 | CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | BEZWADA BIOMEDICAL, LLC (US) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076174-A1 | CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | MME, CTSA, ALG1 | PAM 587/4885TSHR 3963/4885CTH 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.